stockportfolio.pro
IDEAYA Biosciences, Inc. (IDYA)
Healthcare · Biotechnology · NasdaqGS
IDEAYA Biosciences, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $19.54M | $27.94M | $50.93M | $23.39M | $7.00M | $218.71M |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | $-11.86M | $-34.35M | $-41.98M | $-34.49M | $-49.76M | $-58.66M | $-112.96M | $-274.48M | $-113.70M |
| Net margin | — | — | — | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
Source: IDEAYA Biosciences, Inc. SEC filings (10-K).
Explore 9 years of IDEAYA Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IDYA in your portfolio →
IDEAYA Biosciences, Inc. financial history by metric
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences, Inc. — frequently asked questions
What is IDEAYA Biosciences, Inc.'s revenue?
IDEAYA Biosciences, Inc. (IDYA) reported revenue of $218.71M for fiscal year 2025, up 3024.4% from the prior year, according to its SEC filings.
Is IDEAYA Biosciences, Inc. profitable?
No — IDYA reported a net loss of $-113.70M in fiscal 2025.
What is IDYA's P/E ratio?
IDEAYA Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is IDEAYA Biosciences, Inc. growing?
IDYA's revenue grew at roughly 62.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does IDEAYA Biosciences, Inc. have?
As of fiscal year 2025, IDYA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is IDEAYA Biosciences, Inc.'s market cap?
IDEAYA Biosciences, Inc. (IDYA) has a market capitalization of about $2.79B, based on the latest data in our nightly-refreshed cache.
When does IDEAYA Biosciences, Inc.'s fiscal year end?
IDYA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from IDEAYA Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.